Donate For Public and Patients Store Search

S060 - Recent Advances in Bullous Diseases

Monday, March 4; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize both typical and atypical presentations of autoimmune bullous diseases.
  • Develop an understanding of newly recognized pathways of disease pathogenesis of several autoimmune bullous diseases
  • Develop a broader 'tool box' of therapies for patients with autoimmune bullous diseases.

Description

This will be a rapid fire series of short presentations of newest information on the diagnosis, pathogenesis and treatment of pemphigus, pemphigoid, epidermolysis bullosa aquisita and dermatitis herpetiformis. New therapeutic options and their mechanisms of action will be reviewed along with recently identified causes for several of the autoimmune bullous diseases. Speakers will include a broad spectrum of internationally recognized experts in the field.

Disclosures

  • Aoki, Valeria, MD: no financial relationships exist with commercial interests.
  • Caux, Frederic, PhD: LEO Laboratories Ltd (LEO Pharma) – I(Fees); Novartis – A(H); Pierre Fabre Dermatologie – C(H); Principia Biopharma Inc – A(H), I(Fees); Roche Laboratories – I(Fees);
  • Diaz, Luis A., MD: no financial relationships exist with commercial interests.
  • Fairley, Janet A., MD: arGEN-X – C(NC); Immune Pharmaceuticals – I(Grants/Research Funding);
  • Feldman, Ron, MD, PhD: Bioverativ – C(Fees); Cabeletta Bio – C(Fees); Celtaxsys Inc – C(Fees); Galderma USA – Speaker/Faculty Education(Fees);
  • Fivenson, David P., MD: Abbott Laboratories – I(Grants/Research Funding), SP(H); AbbVie – I(Grants/Research Funding), SP(Fees); Amgen – I(Grants/Research Funding); BestDoctors – Independent Contractor(Fees); Bristol-Myers Squibb – I(Grants/Research Funding); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); Eli Lilly and Company – SP(H); Galderma USA – I(Grants/Research Funding); Gerson Lehrman Group – C(Fees); Glenmark Generics Inc. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H); L.E.K. Consulting – C(Fees); LEO Pharma, US – I(Grants/Research Funding); Novum – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding), SP(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding); Symbio – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding);
  • Grando, Sergei A., MD, PhD: no financial relationships exist with commercial interests.
  • Joly, Pascal, MD, PhD: Almirall – C(H); GlaxoSmithKline – C(H); Lilly ICOS LLC – C(H); Novartis Pharmaceuticals Corp. – C(H); Principia Biopharma Inc – C(H); Roche Laboratories – C(H); sanofi-aventis – C(H);
  • Murrell, Dedee F., MD: 3M Pharmaceuticals – C(Grants/Research Funding); Abbott Laboratories – A(H), SP(H); AbbVie – I(Grants/Research Funding); Actavis – Speaker/Faculty Education(H); Almirall – C(H); Amgen – I(Fees); Amicus Therapeutics – A(H); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Ascent Pharmaceuticals – SP(H); Castle Creek Pharmaceuticals – C(Fees); CSL – SP(Grants/Research Funding), SP(H); Delfin Technology – I(EQ); Eli Lilly and Company – A(H); Galderma Laboratories, L.P. – I(Grants/Research Funding), I(OB); Janssen-Ortho Inc. – O(Grants/Research Funding); Leo Pharma Inc – Speaker/Faculty Education(H); Medimmune – I(Grants/Research Funding); Merck Serono – I(Fees), I(Grants/Research Funding); Molynlycke – SP(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Pierre Fabre Dermo-Cosmétique US – SP(H); Principia Biopharma Inc – C(H); Roche Laboratories – A(H), I(Grants/Research Funding); Samumed, LLC – I(Grants/Research Funding); Schering-Plough Corporation – I(Grants/Research Funding), SP(OB); Shire – A(H), I(Grants/Research Funding); Stiefel a GSK company – SP(H); XOMA (US) LLC – I(Grants/Research Funding);
  • Prost Squarcioni, Catherine, MD: no financial relationships exist with commercial interests.
  • Werth, Victoria P., MD: AstraZeneca – A(H); Biogen – C(H), I(Grants/Research Funding); BMS – C(H); Celgene Corporation – C(H), I(Grants/Research Funding); CSL – C(H); Genentech, Inc. – C(H); Gilead Sciences – C(H), I(Grants/Research Funding); Idera Pharmaceuticals, Inc. – C(H); Immune Pharmaceuticals – C(H); Immunotherapeutics – C(H); Janssen Pharmaceuticals, Inc – C(H), I(Grants/Research Funding); Lilly ICOS LLC – C(H); Lupus Foundation of America – C(H); Medimmune – C(H); Neovacs – C(H); Octapharma – C(H); Pfizer Inc. – C(H), I(Grants/Research Funding); Principia Biopharma Inc. – C(H); Resolve Therapeutics – C(H); Roche Laboratories – C(H); Stiefel a GSK company – C(H); Syntimmune, Inc. – C(H), I(Grants/Research Funding); UV Therapeutics – A(ST);
  • Woodley, David T., MD: no financial relationships exist with commercial interests.
  • Zone, John Joseph, MD: Principia Biopharma Inc. – I(NC);
Schedule
Monday, March 4
1:00 PM
Dr. Fivenson / Introduction
1:05 PM
Dr. Joly / Rituximab in Pemphigus- Who and When?
1:25 PM
Dr. Murrell / Bruton Tyrosine Kinase Inhibitors for Pemphigus
1:40 PM
Dr. Caux / FcRn, CAART and Other Emerging Treatment Options for Pemphigus
1:55 PM
Dr. Diaz / Endemic Pemphigus Foliaceous IgG4 Autoantibody Targets That Lead to Acantholysis
2:10 PM
Dr. Grando / Multimodal Treatment of Pemphigus = Multi- vs Monofactorial Pathogenesis
2:25 PM
Dr. Feldman / Biomarkers for Pemphigus
2:40 PM
Dr. Diaz, Dr. Murrell, Dr. Feldman, Dr. Grando, Dr. Caux, and Dr. Joly / Pemphigus Panel Q & A
2:50 PM
Dr. Werth / Rituximab for other AIBDs
3:00 PM
Dr. Zone / The Role of Transglutaminase 3 in Dermatitis Herpetiformis Skin
3:10 PM
Dr. Woodley / Epidermolysis Bullosa Aquisita Update - New Consensus Paper
3:30 PM
Dr. Fairley / IgE Pemphigoid
3:40 PM
Dr. Prost Squarcioni / Drug - Induced AIBDs - PD-1, PDL-1, ACEi, PPi, DDP4i
3:50 PM
Dr. Aoki / Epitope Spreading in PAMS: A Clinical Immunopathologic Basis
Event Details
  • Date
    Monday, March 4
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 209A
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • David P. Fivenson, MD, FAAD
Speakers
  • Catherine Prost Squarcioni, MD
  • David T. Woodley, MD, FAAD - Handout
  • Dedee F. Murrell, MD, FAAD
  • Frederic Caux, PhD
  • Janet A. Fairley, MD, FAAD
  • John Joseph Zone, MD, FAAD - Handout 1, Handout 2
  • Luis A. Diaz, MD, FAAD
  • Pascal Joly, MD, PhD
  • Ron Feldman, MD, PhD, FAAD
  • Sergei A. Grando, MD, PhD, FAAD - Handout
  • Valeria Aoki, MD - Handout
  • Victoria P. Werth, MD, FAAD